| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Metastasis Research Program, Karmanos Cancer Institute, Detroit, Michigan 48201 [H. C. G., Y. H., P. N-M., V. H., A. R.]; Department of Pathology, Radiation Oncology, Wayne State University, School of Medicine, Detroit, Michigan 48201 [A. R.]; Gastrointestinal Cancer Research Laboratory, Henry Ford Health Sciences Center, Detroit, Michigan 48202 [N. M., R. S. B.]
Galectin-3 is a member of the 
-galactoside-binding protein family shown to be involved in tumor progression and metastasis. It has a unique primary structure consisting of three domains: a 12-amino acid leader sequence containing a casein kinase I serine phosphorylation site, which is preceded by a collagenase-sensitive Pro-Gly-rich motif, and a COOH-terminal half encompassing the carbohydrate-binding site. To study the functional role of the unusual leader sequence of galectin-3, a mutant cDNA that causes an 11-amino acid deletion in the NH2-terminal region was generated and expressed in galectin-3-null BT-549 human breast carcinoma cells. Deletion of the NH2 terminus resulted in abolition of the secretion of truncated galectin-3, loss of nuclear localization, and reduced carbohydrate-mediated functions compared with the wild-type protein. When green fluorescent protein was fused to the galectin-3 leader sequence and transiently transfected into BT-549 cells, the uniform cellular distribution of native green fluorescent protein was changed mainly to a nuclear pattern. To further investigate whether the functional changes observed in a galectin-3 with the 11 NH2-terminal amino acids deleted were due to loss of phosphorylation at Ser6, two point mutations were created at this serine: Ser6
Ala and Ser6Glu. No obvious difference was observed in cellular localization between wild-type and Ser6-mutated transfectants. These results suggest a structural role for the NH2 terminus leader motif of galectin-3 in determining its cellular targeting and biological functions independent of phosphorylation.
This article has been cited by other articles:
|
|
 |
|
  R. Shalom-Feuerstein, S. J. Plowman, B. Rotblat, N. Ariotti, T. Tian, J. F. Hancock, and Y. Kloog K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3 Cancer Res., August 15, 2008; 68(16): 6608 - 6616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Kumar and S. L. Deutscher 111In-Labeled Galectin-3-Targeting Peptide as a SPECT Agent for Imaging Breast Tumors J. Nucl. Med., May 1, 2008; 49(5): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nangia-Makker, T. Raz, L. Tait, V. Hogan, R. Fridman, and A. Raz Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast Cancers Cancer Res., December 15, 2007; 67(24): 11760 - 11768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H.M. de Melo, D. Butera, R. S. Medeiros, L. N. d. S. Andrade, S. Nonogaki, F. A. Soares, R. A. Alvarez, A. M. Moura da Silva, and R. Chammas Biological Applications of a Chimeric Probe for the Assessment of Galectin-3 Ligands J. Histochem. Cytochem., October 1, 2007; 55(10): 1015 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Oliveira, P. Frazao, R. Chammas, D. K. Hsu, F. T. Liu, R. Borojevic, C. M. Takiya, and M. C. El-Cheikh Kinetics of mobilization and differentiation of lymphohematopoietic cells during experimental murine schistosomiasis in galectin-3 / mice J. Leukoc. Biol., August 1, 2007; 82(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakahara, V. Hogan, H. Inohara, and A. Raz Importin-mediated Nuclear Translocation of Galectin-3 J. Biol. Chem., December 22, 2006; 281(51): 39649 - 39659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakahara, N. Oka, Y. Wang, V. Hogan, H. Inohara, and A. Raz Characterization of the nuclear import pathways of galectin-3. Cancer Res., October 15, 2006; 66(20): 9995 - 10006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Davidson, S.-Y. Li, A. G. Lohse, R. Vandergaast, E. Verde, A. Pearson, R. J. Patterson, J. L. Wang, and E. J. Arnoys Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import Glycobiology, July 1, 2006; 16(7): 602 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cecchinelli, L. Lavra, C. Rinaldo, S. Iacovelli, A. Gurtner, A. Gasbarri, A. Ulivieri, F. Del Prete, M. Trovato, G. Piaggio, et al. Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced Apoptosis Mol. Cell. Biol., June 15, 2006; 26(12): 4746 - 4757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lagana, J. G. Goetz, P. Cheung, A. Raz, J. W. Dennis, and I. R. Nabi Galectin Binding to Mgat5-Modified N-Glycans Regulates Fibronectin Matrix Remodeling in Tumor Cells Mol. Cell. Biol., April 15, 2006; 26(8): 3181 - 3193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mazurek, Y. J. Sun, J. E. Price, L. Ramdas, W. Schober, P. Nangia-Makker, J. C. Byrd, A. Raz, and R. S. Bresalier Phosphorylation of Galectin-3 Contributes to Malignant Transformation of Human Epithelial Cells via Modulation of Unique Sets of Genes Cancer Res., December 1, 2005; 65(23): 10767 - 10775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Oka, S. Nakahara, Y. Takenaka, T. Fukumori, V. Hogan, H.-o. Kanayama, T. Yanagawa, and A. Raz Galectin-3 Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells Cancer Res., September 1, 2005; 65(17): 7546 - 7553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Ruebel, L. Jin, X. Qian, B. W. Scheithauer, K. Kovacs, N. Nakamura, H. Zhang, A. Raz, and R. V. Lloyd Effects of DNA Methylation on Galectin-3 Expression in Pituitary Tumors Cancer Res., February 15, 2005; 65(4): 1136 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Partridge, C. Le Roy, G. M. Di Guglielmo, J. Pawling, P. Cheung, M. Granovsky, I. R. Nabi, J. L. Wrana, and J. W. Dennis Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis Science, October 1, 2004; 306(5693): 120 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takenaka, T. Fukumori, T. Yoshii, N. Oka, H. Inohara, H.-R. C. Kim, R. S. Bresalier, and A. Raz Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs Mol. Cell. Biol., May 15, 2004; 24(10): 4395 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukumori, Y. Takenaka, T. Yoshii, H.-R. C. Kim, V. Hogan, H. Inohara, S. Kagawa, and A. Raz CD29 and CD7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis Cancer Res., December 1, 2003; 63(23): 8302 - 8311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. John, H. Leffler, B. Kahl-Knutsson, I. Svensson, and G. A. Jarvis Truncated Galectin-3 Inhibits Tumor Growth and Metastasis in Orthotopic Nude Mouse Model of Human Breast Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2374 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshii, T. Fukumori, Y. Honjo, H. Inohara, H.-R. C. Kim, and A. Raz Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest J. Biol. Chem., February 22, 2002; 277(9): 6852 - 6857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Saggiorato, S. Cappia, P. De Giuli, A. Mussa, G. Pancani, P. Caraci, A. Angeli, and F. Orlandi Galectin-3 as a Presurgical Immunocytodiagnostic Marker of Minimally Invasive Follicular Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5152 - 5158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Q. Zhu and J. Ochieng Rapid Release of Intracellular Galectin-3 from Breast Carcinoma Cells by Fetuin Cancer Res., March 1, 2001; 61(5): 1869 - 1873. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Honjo, P. Nangia-Makker, H. Inohara, and A. Raz Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells Clin. Cancer Res., March 1, 2001; 7(3): 661 - 668. [Abstract] [Full Text]
|
|
|
|
|
|
E. A. M. Barboni, S. Bawumia, K. Henrick, and R.C. Hughes Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding Glycobiology, November 1, 2000; 10(11): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mazurek, J. Conklin, J. C. Byrd, A. Raz, and R. S. Bresalier Phosphorylation of the beta -Galactoside-binding Protein Galectin-3 Modulates Binding to Its Ligands J. Biol. Chem., November 10, 2000; 275(46): 36311 - 36315. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
